-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Atorvastatin + Ezetimibe) in Hypercholesterolemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Atorvastatin + Ezetimibe) in Hypercholesterolemia Drug Details: Atorvastation in combination with ezetimibe is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Atorvastatin + Ezetimibe) in Hyperlipidemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Atorvastatin + Ezetimibe) in Hyperlipidemia Drug Details:Atorvastation in combination with ezetimibe is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Atorvastatin + Ezetimibe) in Hypercholesterolemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Atorvastatin + Ezetimibe) in Hypercholesterolemia Drug Details:Atorvastation in combination with ezetimibe is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Atorvastatin + Fluconazole + Minocycline) in Primary Progressive Multiple Sclerosis (PPMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Atorvastatin + Fluconazole + Minocycline) in Primary Progressive Multiple Sclerosis (PPMS) Drug Details: A fixed-dose...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Atorvastatin + Fluconazole + Minocycline) in Relapsing Multiple Sclerosis (RMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Atorvastatin + Fluconazole + Minocycline) in Relapsing Multiple Sclerosis (RMS) Drug Details: A fixed-dose combination...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Evolocumab in Hypercholesterolemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Evolocumab in HypercholesterolemiaDrug Details: Evolocumab (AMG-145, Repatha) is a monoclonal antibody acts as lipid modifying agent....
-
Company Profile
![]()
Ferring International Center SA – Company Profile
Ferring International Center SA (Ferring), a subsidiary of Ferring Holding SA research, develops and markets pharmaceutical products. The company offers products in the fields of reproductive health, endocrinology, gastroenterology, urology, and orthopedics. Its major products include Rekovelle (follitropin delta), for controlled ovarian stimulation, Menopur (HP-hMG) for female and male infertility, and Firmagon (degarelix) for prostate cancer. Its pipeline products encompass rHCG for Triggering FFM and rFSH for male infertility for infertility, FE 202767 for Lactation, RBX2660 enema for difficile infection...
Add to Basket -
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – rosuvastatin ER
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry rosuvastatin ER Drug Details Rosuvastatin extended-release capsule (LYN-047) is under development for the treatment...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – (atorvastatin + ezetimibe)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (atorvastatin + ezetimibe) Drug Details Atorvastation in combination with ezetimibe is under development for...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – (ezetimibe + rosuvastatin + telmisartan)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (ezetimibe + rosuvastatin + telmisartan) Drug Details NVP-1805 is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.